Granted Patent
B2
US 12,521,434 · App. 17/318,914 · Granted Jan 13, 2026
Hematopoietic cells with a modified CD antigen for reducing side effects of cancer immunotherapy
Inventors:
Michael Lutteropp (Bergisch Gladbach, DE); Anne Richter (Bergisch Gladbach, DE); Andrew Kaiser (Bergisch Gladbach, DE); Mario Assenmacher (Bergisch Gladbach, DE); Stefan Miltenyi (Bergisch Gladbach, DE)
Assignee:
MILTENYI BIOTEC GMBH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
Claims (13)
1 . An effective amount of a pharmaceutical product that is configured for reducing side effects of immunotherapy in a human subject,
wherein the immunotherapy comprises removing target cells from the subject that express a particular target antigen;
wherein the target antigen is a human cluster of differentiation (CD) antigen;
wherein the product comprises a population of human hematopoietic progenitor cells that were obtained from the subject or another donor, and then genetically altered to knock out or otherwise silence genes encoding the target antigen, thereby adapting the hematopoietic progenitor cells and progeny thereof to not express the target antigen;
wherein the pharmaceutical product further comprises one or more pharmaceutical excipients that are configured for inclusion in a pharmaceutical product formulated for human administration;
wherein the side effects of the immunotherapy are a consequence of concurrent removal from the subject of non-target cells that also express the target antigen; and
wherein the genetically altered hematopoietic progenitor cells of the pharmaceutical product, upon administration to the subject, are resistant to elimination by the immunotherapy as a consequence of not expressing the target antigen;
wherein the effective amount contains an amount of the genetically altered hematopoietic progenitor cells that is effective in reconstituting hematopoietic function and reducing the side effects of the immunotherapy in the subject.
2 . The effective amount of the pharmaceutical product according to claim 1 , wherein absence of the target antigen on the genetically altered hematopoietic progenitor cells does not adversely affect hematopoietic cell function.
3 . The effective amount of the pharmaceutical product according to claim 1 , in combination with a sample of the hematopoietic progenitor cells obtained from the subject that have not been genetically altered.
4 . The effective amount of the pharmaceutical product according to claim 1 , in combination with a means for specifically removing target cells from the subject that express said target antigen.
5 . The effective amount of the pharmaceutical product according to claim 1 , in combination with a population of T or NK cells that recognize and remove the target cells.
6 . The effective amount of the pharmaceutical product according to claim 1 , in combination with a population of immune effector cells bearing a chimeric antigen receptor (CAR) or a T cell receptor (TCR) that is specific for the target antigen.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 24, 2025
From: LUTTEROPP, MICHAEL; RICHTER, ANNE; KAISER, ANDREW; ASSENMACHER, MARIO; MILTENYI, STEFAN
To: MILTENYI BIOTEC GMBH
Reel/Frame 070605/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 24, 2025
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 070612/0198 →
Priority Claims (1)
DE 102014224071.9
· Nov 26, 2014
· national
Continuity (3)
References Cited (153)
US 20150329640A1
· Finer
· 2015
[cited by examiner]
EP 2711418A1
· 2014
[cited by applicant]
EP 3025719B1
· 2018
[cited by applicant]
EP 3105317B1
· 2018
[cited by applicant]
WO 2012012667A2
· 2012
[cited by applicant]
WO 2012082841A2
· 2012
[cited by applicant]
WO 2014059173A2
· 2014
[cited by applicant]
WO 2014191128A1
· 2014
[cited by applicant]
WO 2015121454A1
· 2015
[cited by applicant]
WO WO2016011210A2
· 2016
[cited by examiner]
WO 2017066760A1
· 2017
[cited by applicant]
WO 2017079400A1
· 2017
[cited by applicant]
Casucci et al. “CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma”, Blood. Nov. 14, 2013;122(20):3461-72. (Year: 2013).
[cited by examiner]
Henry et al. “Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance”, Blood. Mar. 25, 2010;115(12):2420-9. (Year: 2010).
[cited by examiner]
Bendall et al. “Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34 cells”, Leukemia. Jul. 2000;14(7):1239-46. (Year: 2000).
[cited by examiner]
Vera et al. “T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells”, Blood. Dec. 1, 2006;108(12):3890-7 (Year: 2006).
[cited by examiner]
Uchida et al. “Mouse CD20 expression and function”, Int Immunol. Jan. 2004;16(1):119-29 (Year: 2004).
[cited by examiner]
“Autologous T-Cells Genetically Modified at the CCR5 Gene by Zink Finger Nucleases SB-728 for HIV”, Clinical study listed on Clinicaltrials.gov website under Identifier NCT00842634, Accessed from Internet on Mar. 12, 20…
[cited by applicant]
“CAR T-Cell Therapy: Engineering Patients' Immune Cells to Treat Their Cancers”, National Cancer Institute, Available online at: http://www.cancer.gov/aDout-cancer/treatment/research/car-t-cens, May 18, 2015, 6 pages.
[cited by applicant]
“CD33 [Uniport ID: P20138]”, Available online at: https://register.epo.org/application?number=EP15196309&Ing=en&tab=doclist, Accessed from Internet on Feb. 15, 2021, 45 pages.
[cited by applicant]
“Protein (Amino Acid) Sequence Data for CD33, CD34, CD45, CD123, CD133, and CD19”, From Swiss-Prot database dated Sep. 5 and Oct. 3, 2012, 2012, 9 pages.
[cited by applicant]
“Raji (ATCC® CCL86™)”, Available online at: http://www.lgcstandards-atcc.org/Products/All/CCL-86.aspx?geo, Accessed from Internet on Feb. 15, 2021, 2 pages.
[cited by applicant]
“Vor Biopharma”, Available online at: http://www.vorbiopharma.com, Accessed from Internet on: Feb. 15, 2021, 3 pages.
[cited by applicant]
U.S. Appl. No. 14/952,448, Final Office Action mailed on Jun. 21, 2018, 8 pages.
[cited by applicant]
U.S. Appl. No. 14/952,448, First Action Interview Pilot Program Pre-Interview Communication mailed on Jan. 23, 2018, 3 pages.
[cited by applicant]
U.S. Appl. No. 14/952,448, Notice of Allowability mailed on Dec. 28, 2018, 2 pages.
[cited by applicant]
U.S. Appl. No. 14/952,448, Notice of Allowance mailed on Nov. 30, 2018, 8 pages.
[cited by applicant]
U.S. Appl. No. 14/952,448, Restriction Requirement mailed on Aug. 10, 2017, 8 pages.
[cited by applicant]
U.S. Appl. No. 16/005,466, First Action Interview Pilot Program Pre-Interview Communication mailed on Nov. 30, 2020, 3 pages.
[cited by applicant]
U.S. Appl. No. 16/005,466, Notice of Allowance mailed on Apr. 5, 2021, 9 pages.
[cited by applicant]
U.S. Appl. No. 16/005,466, Supplemental Notice of Allowability mailed on May 13, 2021, 2 pages.
[cited by applicant]
Anaya et al., “Autoimmunity: From Bench to Bedside”, El Rosario University Press, Jul. 18, 2013, 70 pages.
[cited by applicant]
Anurathapan et al., “Engineered T Cells for Cancer Treatment”, Cytotherapy, vol. 16, No. 6, Jun. 2014, pp. 713-733.
[cited by applicant]
Bailey et al., “M.V. Gene Editing for Immune Cell Therapies”, Nature Biotechnology, vol. 37, No. 12, Jun. 3, 2019, pp. 1425-1434.
[cited by applicant]
Belicha-Villanueva et al., “What Is the Role of Alternate Splicing in Antigen Presentation by Major Histocompatibility Complex Class I Molecules”, Immunologic Research, vol. 46, No. 1-3, Mar. 2010, pp. 32-44.
[cited by applicant]
Bergom et al., “An Alternatively Spliced Isoform of Pecam-1 Is Expressed at High Levels in Human and Murine Tissues, and Suggests a Novel Role for the C-terminus of PECAM-1 in Cytoprotective Signalling”, Journal of Cell…
[cited by applicant]
Borot et al., “Gene-edited Stem Cells Enable CC33-directed Immune Therapy for Myeloid Malignancies”, Proceedings of the National Academy of Sciences USA, vol. 116, No. 24, Jun. 11, 2019, pp. 11978-11987.
[cited by applicant]
Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia”, Science Translational Medicine, vol. 5, No. 177, Mar. 20, 2013, pp. 1-19.
[cited by applicant]
Bubien et al., “Transfection of the CD20 Cell Surface Molecule Into Ectopic Cell Types Generates a Ca2+ Conductance Found Constitutively in B Lymphocytes”, Journal of Cell Biology, vol. 121, No. 5, Jun. 1993, pp. 1121-1…
[cited by applicant]
Cho et al., “Targeted Genome Engineering in Human Cells with the Cas9 RNA-Guided Endonuclease”, Nature Biotechnology, vol. 31, No. 3, 2013, pp. 230-232.
[cited by applicant]
Cong et al., “Multiplex Genome Engineering Using CRISPR/Cas Systems”, Science, vol. 339, No. 6121, Feb. 15, 2013, pp. 819-823.
[cited by applicant]
Cradick et al., “CRISPR/cas9 Systems Targeting-globin and CCR5 Genes have Substantial off-target Activity”, Nucleic Acids Research, vol. 41, No. 20, 2013, pp. 9584-9592.
[cited by applicant]
Davila et al., “Efficacy and Toxicity Management of 19-28z Car T Cell Therapy in B Cell Acute Lymphoblastic Leukemia”, Science Translational Medicine, vol. 6, No. 224, Feb. 19, 2014, pp. 1-23.
[cited by applicant]
De Oliveira et al., “Modification of Hematopoietic Stem/progenitor Cells With CD19-specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy”, Human Gene Therapy, vol. 24, No. 10, Oct. 2013, pp. 8…
[cited by applicant]
European Patent Application No. EP1519609.7, Response to the Opposition mailed on Nov. 18, 2019, 39 pages.
[cited by applicant]
European Patent Application No. EP15196309, European Search Report mailed Feb. 17, 2016, 2 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Auxiliary Requests Accompanying Written Submission: Miltenyi, Mar. 2, 2021, 31 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Communication in Advance of Oral Proceedings: Opponent, Mar. 5, 2021, 45 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Consolidated List of Cited Documents, Mar. 17, 2021, 4 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Response to Opponent's Submission of Mar. 5, 2021: Miltenyi, Mar. 12, 2021, 9 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Response to Patentee's Submission of Jan. 19, 2021: Opponent, Mar. 5, 2021, 16 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Results of Oral Proceedings, Mar. 19, 2021, 1 page.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Supplementary Response to the Objection Raised By The Opponent: Miltenyi, Mar. 17, 2021, 14 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Opposition—Written Submission in Response to Communication from Opposition Division: Miltenyi, Mar. 2, 2021, 13 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Response to First Summons mailed on Aug. 19, 2020, 16 pages.
[cited by applicant]
European Patent Application No., EP15196309.7, Response to Opposition mailed on Aug. 21, 2020, 25 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Response to Second Summons mailed on Jan. 19, 2021, 25 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Summons to attend Oral Proceeding mailed on Mar. 6, 2020, 11 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Summons to Attend Oral Proceedings mailed on Sep. 29, 2020, 8 pages.
[cited by applicant]
European Patent Application No. EP16856410.2, European Search Report mailed on Apr. 25, 2019, 9 pages.
[cited by applicant]
European Patent Application No. EP3025719, Notice of Opposition mailed on Jun. 26, 2019, 34 pages.
[cited by applicant]
Epstein et al., “Morphological and Virological Investigations on Cultured Burkitt Tumor Lymphoblasts (Strain Raji)”, Journal of the National Cancer Institute, vol. 37, No. 4, Oct. 1966, pp. 547-559.
[cited by applicant]
Falkenburg et al., “T Cell Therapy in Allogeneic Stem Cell Transplantation”, Biology of Blood and Marrow Transplantation, vol. 14, 1 Supplement 1, Jan. 2008, pp. 136-141.
[cited by applicant]
Gill et al., “Preclinical Targeting of Human Acute Myeloid Leukemia and Myeloablation Using Chimeric Antigen Receptor-modified T Cells”, Blood, vol. 123, No. 15, Apr. 10, 2014, pp. 2343-2354.
[cited by applicant]
Gomes-Silva et al., “CD7-Edited T Cells Expressing a CD7-specific CAR for the Therapy of T-cell Malignancies”, Blood, vol. 130, No. 3, Jul. 20, 2017, pp. 285-296.
[cited by applicant]
Grupp et al., “Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia”, The New England Journal of Medicine, vol. 368, No. 16, Apr. 18, 2013, pp. 1509-1518.
[cited by applicant]
Henig et al., “Hematopoietic Stem Cell Transplantation—50 Years of Evolution and Future Perspectives”, Rambam Maimonides Medical Journal, vol. 5, No. 4, Oct. 29, 2014, 15 pages.
[cited by applicant]
Hinrichs et al., “Reassessing Target Antigens for Adoptive T-cell Therapy”, Nature Biotechnology, vol. 31, No. 11, Oct. 20, 2013, pp. 999-1008.
[cited by applicant]
Holmes, “CD45: All is Not Yet Crystal Clear”, Immunology 2005, vol. 117, 2005, pp. 145-155.
[cited by applicant]
Janeway et al., “The Immune System in Health and Disease”, Immunobiology, 1994, 5 pages.
[cited by applicant]
Kebriaei et al., “Infusing CD-19-directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-cell Transplantation for Advanced B-lymphoid Malignancies”, Human Gene Therapy, vol. 23, …
[cited by applicant]
Kim et al., “Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CART Cell Immunotherapy for Acute Myeloid Leukemia”, Cell, vol. 173, No. 6, May 31, 2018, pp. 1439-1453.
[cited by applicant]
Kim et al., “Precision Genome Engineering with Programmable DNA-Nicking Enzymes”, Genome Research, vol. 22, 2002, pp. 1327-1333.
[cited by applicant]
Klein et al., “Epitope Interactions of Monoclonal Antibodies Targeting CD20 and Their Relationship to Functional Properties”, MAbs, vol. 5, No. 1, Jan.-Feb. 2013, pp. 22-33.
[cited by applicant]
Kolb, “Graft-versus-Leukemia Effects of Transplantation and Donor Lymphocytes”, Blood, vol. 112, No. 12, Dec. 1, 2008, pp. 4371-4383.
[cited by applicant]
Koo et al., “Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9”, Molecules and Cells, vol. 38, No. 6, 2015, pp. 475-481.
[cited by applicant]
Kuijpers et al., “CD20 Deficiency in Humans Results in Impaired T Cell-independent Antibody Responses”, Journal of Clinical Investigation, vol. 120, No. 1, Jan. 4, 2010, pp. 214-222.
[cited by applicant]
Lamers et al., “Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T Cells: Clinical Evaluation and Management of on-target Toxicity”, Molecular Therapy, vol. 21, No. 4, Apr. 2013, pp. 904-912.
[cited by applicant]
Leisegang et al., “MHC-restricted Fratricide of Human Lymphocytes Expressing Survivin-specific Transgenic T Cell Receptors”, Journal of Clinical Investigation, vol. 120, No. 11, Nov. 2010, pp. 3869-3877.
[cited by applicant]
Mali et al., “RNA-Guided Human Genome Engineering Via Cas9”, Science, vol. 339, No. 6121, Feb. 15, 2013, 8 pages.
[cited by applicant]
Manghwar et al., “CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects”, Advanced Science, vol. 7, 2020, pp. 1-16.
[cited by applicant]
Marelli-Berg et al., “An Immunologist's Guide to CD31 Function in T-cells”, Journal of Cell Science, vol. 126, Pt. 11, Jun. 1, 2013, pp. 2343-2352.
[cited by applicant]
Morgan et al., “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2”, Molecular Therapy, vol. 18, No. 4, Apr. 2010, pp. 843-851.
[cited by applicant]
Morgan et al., “Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRVIII and Development of Adoptive Cell Therapy for Glioma”, Human Gene Therapy, vol. 23, No. 10, Oct. 2012, pp. 1043-1053.
[cited by applicant]
Porter et al., “Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia”, The New England journal of Medicine, vol. 365, No. 8, Aug. 25, 2011, pp. 725-733.
[cited by applicant]
Roberts et al., “CD45-deficient Severe Combined Immunodeficiency Caused by Uniparental Disomy”, Proceedings of the National Academy of Sciences USA, vol. 109, No. 26, Jun. 26, 2012, pp. 10456-10461.
[cited by applicant]
Schendel et al., “Limitations for TCR Gene Therapy by MHC-restricted Fratricide and TCR-mediated Hematopoietic Stem Cell Toxicity”, Oncoimmunology, vol. 2, No. 1, Jan. 2013, 3 pages.
[cited by applicant]
Shono et al., “Bone Marrow Graft-versus-host Disease: Early Destruction of Hematopoietic Niche After MHC-mismatched Hematopoietic Stem Cell Transplantation”, Blood, vol. 115, No. 26, Jul. 1, 2010, pp. 5401-5411.
[cited by applicant]
Taniguchi et al., “2B4 Inhibits NK-cell Fratricide”, Blood, vol. 110, No. 6, Sep. 15, 2007, pp. 2020-2023.
[cited by applicant]
Tebas et al., “Gene Editing of CCRS in Autologous CD4 T Cells of Persons Infected with HIV”, The New England Journal of Medicine, vol. 370, No. 10, Mar. 6, 2014, pp. 901-910.
[cited by applicant]
Uchiyama et al., “Development of Novel Humanized Anti-CD20 Antibodies Based on Affinity Constant and Epitope”, Cancer Science, vol. 101, No. 1, Jan. 1, 2010, pp. 201-209.
[cited by applicant]
Ukena et al., “Human Regulatory T Cells in Allogeneic Stem Cell Transplantation”, Blood, vol. 118, No. 13, Sep. 29, 2011, pp. e82-e92.
[cited by applicant]
Urnov et al., “Genome Editing with Engineered Zinc Finger Nucleases”, Nature Reviews Genetics, Document D44, vol. 9, No. 11, Sep. 2010, pp. 636-646.
[cited by applicant]
Zebedee et al., “Comparison of Mouse Ly5 and Ly5b Leucocyte Common Antigen Alleles”, Developmental Immunology, vol. 1, No. 4, Feb. 1991, pp. 243-254.
[cited by applicant]
Zernich et al., “Natural HLA Class I Polymorphism Controls the Pathway of Antigen Presentation and Susceptibility to Viral Evasion”, Journal of Experimental Medicine, vol. 200, No. 1, Jul. 5, 2004, pp. 13-24.
[cited by applicant]
European Patent Application No. EP15196309.7, Brief Communication—Opposition Proceedings mailed Mar. 23, 2021, 16 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Transmittal of Decision / Summons—Opposition mailed Apr. 28, 2021, 78 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Decision Revoking the European Patent, dated Apr. 28, 2021, 27 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Notice of Appeal dated Apr. 28, 2021, 4 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Statement of Grounds of Appeal mailed Sep. 7, 2021, 44 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Main Request During Appeals Procedure mailed Sep. 7, 2021, 2 pages.
[cited by applicant]
Wang et al., “HM1.24 (CD317) is a Novel Target Against Lung Cancer for Immunotherapy Using Anti-HM1.24 Antibody,” Cancer Immunology Immunotherapy, 2009, Doi:10.1007/S00262-008-0612-4, pp. 967-976.
[cited by applicant]
Laplana et al., “Association of BST-2 Gene Variants with HIV Disease Progression Underscores the Role of BST-2 in HIV Type 1 Infection,” The Journal of Infectious Diseases, vol. 207.3, 2013, pp. 411-419.
[cited by applicant]
Schnittger et al., “D324N Single-Nucleotide Polymorphism in the FLT3 Gene is Associated with Higher Risk of Myeloid Leukemias,” Genes, Chromosomes & Cancer, vol. 45,4, 2006, Doi:10.1002/Gcc.20294, pp. 332-337.
[cited by applicant]
Chen et al., “A New Isoform of Interleukin-3 Receptor α with Novel Differentiation Activity and High Affinity Binding Mode,” The Journal of Biological Chemistry, vol. 284, 9, Feb. 27, 2009, pp. 5763-5773.
[cited by applicant]
Hermansen et al., “Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma,” The Journal of Histochemistry and Cytochemistry, Official Journal of The Histochemistry S…
[cited by applicant]
Pohl et al., “Pharmacogenetic Profiling of CD133 is Associated with Response Rate (RR) and Progression-Free Survival (PFS) in Patients with Metastatic Colorectal Cancer (mCRC), Treated with Bevacizumab-Based Chemotherap…
[cited by applicant]
Jaiswal et al. “CD47 Is Up-Regulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis,” Cell vol. 138, 2, Jul. 23, 2009, Doi:10.1016/j.cell.2009.05.046, pp. 271-285.
[cited by applicant]
Lascorz et al., “Association Study Identifying Polymorphisms in CD47 and other Extracellular Matrix Pathway Genes as Putative Prognostic Markers for Colorectal Cancer,” International Journal of Colorectal Disease, vol. …
[cited by applicant]
Stanton et al., “A High-Frequency Polymorphism in Exon 6 of the CD45 Tyrosine Phosphatase Gene (PTPRC) Resulting in Altered Isoform Expression,” Proc Natl Acad Sci U S A., May 13, 2003, vol. 100, No. 10, doi: 10.1073/pn…
[cited by applicant]
Holmes, “CD45: All is Not Yet Crystal Clear,” Immunology, vol. 117, 2006, pp. 145-155.
[cited by applicant]
Teeling et al. “The Biological Activity of Human CD20 Monoclonal Antibodies is Linked to Unique Epitopes on CD20,” Journal of Immunology, vol. 177, 2006, pp. 362-371.
[cited by applicant]
Ding et al., “Single Nucleotide Polymorphisms of CD20 Gene and Their Relationship with Clinical Efficacy of R-CHOP in Patients with Diffuse large B Cell Lymphoma,” Cancer Cell International, vol. 13, 58, 2013, 7 pages.
[cited by applicant]
Experimenter: Dr. Dominik Lock / Team Coordinator R&D Gene Immunotherapy, 4 pages.
[cited by applicant]
Experimenter: Dr. Eleni Papanikolaou, / Manager, Hemopoietic Stem Cell Gene Therapy, 8 pages.
[cited by applicant]
Sequences of Antigens, 16 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Auxiliary Request (marked-up) mailed Sep. 7, 2021, 21 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Amended Description with Annotations for new MR mailed Sep. 10, 2021, 46 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Reply to Appeal mailed Jan. 21, 2022, 41 pages.
[cited by applicant]
Murphy et al., “Janeway's Immunobiology,” Seventh Edition, Garland Science, Taylor & Francis Group, LLC; 2008. 26 pages.
[cited by applicant]
Zikherman et al. “Quantitative Differences in CD45 Expression Unmask Functions for CD45 in B-Cell Development, Tolerance, and Survival,” Proceedings of the National Academy of Sciences of the United States of America, v…
[cited by applicant]
European Patent Application No. EP15196309.7, Summons to Oral Proceedings mailed Sep. 28, 2022, 3 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Communication of the Board of Appeal pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal dated Dec. 8, 2022, 14 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, In Response to the Communication pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal mailed Jan. 17, 2023, 13 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Letter Accompanying Subsequently filed Items mailed Jan. 17, 2023, 13 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Auxiliary Request (marked-up) mailed Jan. 17, 2023, 13 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, In Response to the Communication pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal mailed Mar. 16, 2023, 23 pages.
[cited by applicant]
Wang, et al., “State-Of-The-Art Human Gene Therapy: Part I. Gene Delivery Technologies,” Discovery Medicine, vol. 18, 2014, pp. 67-77.
[cited by applicant]
Wang, et al., “State-Of-The-Art Human Gene Therapy: Part I. Gene Delivery Technologies,” Abstract, Discovery Medicine, vol. 18, 2014, 2 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Submission Concerning Oral Proceedings on Jul. 18, 2023, mailed May 17, 2023, 12 pages.
[cited by applicant]
European Patent Application No. EP15196309.7, Oppenent's Reply to the Board's Preliminary Opinion and the Patentee's (P's) submission of Jan. 17, 2023, and Mar. 16, 2023, mailed May 19, 2023, 18 pages.
[cited by applicant]
European Patent Application No. Oral Proceedings: Confirmation Interpreters Jul. 13, 2023, 2 pages.
[cited by applicant]
U.S. Appl. No. 17/472,461 , Non-Final Office Action, Mailed On Mar. 2, 2022, 15 pages.
[cited by applicant]
U.S. Appl. No. 17/472,461 , Notice of Allowance, Mailed On Jun. 13, 2022, 10 pages.
[cited by applicant]
U.S. Appl. No. 18/186,730 , Notice of Allowance, Mailed On Sep. 7, 2023, 9 pages.
[cited by applicant]
U.S. Appl. No. 18/418,078 , “Corrected Notice of Allowability”, filed Jan. 22, 2025, 2 pages.
[cited by applicant]
U.S. Appl. No. 18/418,078 , Non-Final Office Action, Mailed On Sep. 17, 2024, 20 pages.
[cited by applicant]
U.S. Appl. No. 18/418,078 , Notice of Allowance, Mailed On Dec. 19, 2024, 7 pages.
[cited by applicant]
U.S. Appl. No. 18/732,517 , Non-Final Office Action, Mailed On Oct. 17, 2024, 10 pages.
[cited by applicant]
U.S. Appl. No. 18/732,517 , Notice of Allowance, Mailed On Feb. 5, 2025, 10 pages.
[cited by applicant]
EP15196309.7 , “Response to Second Summons”, Jan. 19, 2021, 11 pages.
[cited by applicant]
Holt et al., “Human Hematopoietic Stem/Progenitor Cells Modified by Zinc-Finger Nucleases Targeted to CCR5 Control HIV-1 in Vivo”, Nature Biotechnology, vol. 28, No. 8, Aug. 2010, pp. 839-847.
[cited by applicant]